Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

BioAge Labs (BIOA) Preferred Shares Issued (2024)

BioAge Labs' Preferred Shares Issued history spans 1 years, with the latest figure at $170.0 million for Q1 2024.

On a quarterly basis, Preferred Shares Issued changed N/A to $170.0 million in Q1 2024 year-over-year; TTM through Dec 2024 was $170.0 million, a N/A change, with the full-year FY2024 number at $170.0 million, changed N/A from a year prior.
Preferred Shares Issued hit $170.0 million in Q1 2024 for BioAge Labs.
Over the last five years, Preferred Shares Issued for BIOA hit a ceiling of $170.0 million in Q1 2024 and a floor of $170.0 million in Q1 2024.